Respiratory Medication Adherence: Toward a Common Language and a Shared Vision

Eric Van Ganse, David Price

Research output: Contribution to journalArticle

2 Citations (Scopus)
4 Downloads (Pure)

Abstract

The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.
Original languageEnglish
Pages (from-to)799-801
Number of pages3
JournalThe Journal of Allergy and Clinical Immunology: In Practice
Volume4
Issue number5
Early online date30 Aug 2016
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Medication Adherence
Language
Asthma
Therapeutics
Chronic Disease
Costs and Cost Analysis
Biological Therapy
Cost-Benefit Analysis
Delivery of Health Care
Pressure

Cite this

Respiratory Medication Adherence : Toward a Common Language and a Shared Vision. / Van Ganse, Eric; Price, David.

In: The Journal of Allergy and Clinical Immunology: In Practice, Vol. 4, No. 5, 09.2016, p. 799-801.

Research output: Contribution to journalArticle

@article{cdba04a25b4f45f5ad0cc71269ed0a44,
title = "Respiratory Medication Adherence: Toward a Common Language and a Shared Vision",
abstract = "The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.",
author = "{Van Ganse}, Eric and David Price",
note = "Part of this work, conducted by E. Van Ganse, has been performed in the context of the ASTRO-LAB project, which received funding from the European Community's 7th Framework (FP7/2007-2013) under grant agreement no. 282593. Teva supported the meeting costs at which the concepts in this paper were discussed by the co-authors and the open access publication fee for this article. The authors had full editorial control over the ideas presented.",
year = "2016",
month = "9",
doi = "10.1016/j.jaip.2016.04.006",
language = "English",
volume = "4",
pages = "799--801",
journal = "The Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Respiratory Medication Adherence

T2 - Toward a Common Language and a Shared Vision

AU - Van Ganse, Eric

AU - Price, David

N1 - Part of this work, conducted by E. Van Ganse, has been performed in the context of the ASTRO-LAB project, which received funding from the European Community's 7th Framework (FP7/2007-2013) under grant agreement no. 282593. Teva supported the meeting costs at which the concepts in this paper were discussed by the co-authors and the open access publication fee for this article. The authors had full editorial control over the ideas presented.

PY - 2016/9

Y1 - 2016/9

N2 - The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.

AB - The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.

U2 - 10.1016/j.jaip.2016.04.006

DO - 10.1016/j.jaip.2016.04.006

M3 - Article

VL - 4

SP - 799

EP - 801

JO - The Journal of Allergy and Clinical Immunology: In Practice

JF - The Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 5

ER -